ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 105 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 1.89 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $225,713 | -36.6% | 18,086 | -11.3% | 0.00% | – |
| Q1 2024 | $355,992 | +41.8% | 20,389 | -22.6% | 0.00% | – |
| Q4 2023 | $250,973 | +117.5% | 26,335 | +153.6% | 0.00% | – |
| Q3 2023 | $115,388 | -64.3% | 10,386 | +45.4% | 0.00% | – |
| Q4 2022 | $323,620 | +7.2% | 7,144 | +24.4% | 0.00% | – |
| Q3 2022 | $302,000 | -68.2% | 5,742 | -71.2% | 0.00% | -100.0% |
| Q2 2022 | $950,000 | -35.4% | 19,972 | -1.7% | 0.00% | -50.0% |
| Q1 2022 | $1,471,000 | +18.1% | 20,324 | +17.7% | 0.00% | +100.0% |
| Q4 2021 | $1,246,000 | +83.0% | 17,269 | +45.1% | 0.00% | 0.0% |
| Q3 2021 | $681,000 | +28.7% | 11,904 | -0.0% | 0.00% | 0.0% |
| Q2 2021 | $529,000 | +142.7% | 11,906 | +126.0% | 0.00% | – |
| Q4 2020 | $218,000 | -8.4% | 5,269 | +0.6% | 0.00% | – |
| Q3 2020 | $238,000 | -76.6% | 5,236 | -74.2% | 0.00% | -100.0% |
| Q2 2020 | $1,019,000 | +11.5% | 20,295 | +37.7% | 0.00% | 0.0% |
| Q4 2019 | $914,000 | – | 14,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,599,109 | $63,277,000 | 8.68% |
| SENZAR ASSET MANAGEMENT, LLC | 566,903 | $22,432,000 | 6.58% |
| Sarissa Capital Management LP | 105,000 | $4,155,000 | 1.60% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 136,637 | $5,407,000 | 1.41% |
| RA Capital Management | 250,000 | $9,893,000 | 1.17% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 110,515 | $4,373,000 | 0.99% |
| Ghost Tree Capital, LLC | 35,000 | $1,385,000 | 0.75% |
| WALL STREET ASSOCIATES | 159,100 | $6,296,000 | 0.65% |
| BAILARD, INC. | 91,500 | $3,621,000 | 0.56% |
| EAM Investors, LLC | 62,768 | $2,484,000 | 0.50% |